ARTICLE | Clinical News
SB1518 regulatory update
October 25, 2010 7:00 AM UTC
The European Commission granted Orphan Drug designation for S*BIO's SB1518 to treat myelofibrosis. The oral janus kinase-2 ( JAK-2)-selective kinase inhibitor is in Phase II testing for the indicatio...